Assessing Real-World Data Quality: The Application of Patient Registry Quality Criteria to Real-World Data and Real-World Evidence

被引:22
作者
Gliklich, Richard E. [1 ,2 ]
Leavy, Michelle B. [1 ]
机构
[1] OMI Inc, 800 Boylston St,Suite 1410, Boston, MA 02199 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
关键词
21st Century Cures Act; medical product evaluation; electronic health records; product registries; disease registries; TASK-FORCE; GUIDELINES; CHECKLIST;
D O I
10.1007/s43441-019-00058-6
中图分类号
R-058 [];
学科分类号
摘要
The use of real-world data and real-world evidence to inform health care decisions is increasing. Yet, the variable quality of these data and the lack of widely-accepted criteria by which to assess quality create uncertainty about how and when to use these data and the associated evidence in decision making. Patient registries are an important source of real-world data and real-world evidence. The good practices and evaluation criteria developed for patient registries are highly relevant to real-world data and real-world evidence and offer a foundation for a unified set of quality criteria that can be applied across sources of real-world data and real-world evidence intended for use in medical product evaluation.
引用
收藏
页码:303 / 307
页数:5
相关论文
共 25 条
[1]  
[Anonymous], ISPOR GOOD PRACT OUT
[2]  
[Anonymous], LUT 035 DRUG COAT BA
[3]  
[Anonymous], List of Pregnancy Exposure Registries
[4]  
Berger M, A framework for regulatory use of realworld evidence
[5]   Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making [J].
Berger, Marc L. ;
Sox, Harold ;
Willke, Richard J. ;
Brixner, Diana L. ;
Eichler, Hans-Georg ;
Goettsch, Wim ;
Madigan, David ;
Makady, Amr ;
Schneeweiss, Sebastian ;
Tarricone, Rosanna ;
Wang, Shirley V. ;
Watkins, John ;
Daniel Mullins, C. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (09) :1033-1039
[6]  
Clinical Trials Transformation Initiative, 2023, CTTI recommendations: registry trials
[7]  
Dreyer NA, 2010, AM J MANAG CARE, V16, P467
[8]   Guidelines for good pharmacoepidemiology practices (GPP) [J].
Epstein, Mark .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (02) :200-208
[9]  
Gliklich RE., 2014, M L. registries for evaluating patient outcomes: a User's guide. 3rd edition. Two volumes. (prepared by the outcome DEcIDE center [outcome sciences, Inc., V13
[10]  
International Medical Device Regulators Forum, PAT REG ESS PRINC